Jalen Pitre

Cornerback

Age: 26
Free Agency: 2029 (UFA)
Accrued Seasons: 3
  • 2025 Salary Cap Charge: $5,432,020 (1.88% of cap)
  • 2025 Cash Payout: $12,156,000 (4.09% of spending)
  • 2025 Cash to Cap Ratio: 2.24
  • Contract Value: $39,000,000 ($13,000,000 APY)
  • Fully Guaranteed Money: $20,656,000
  • Contract Ranking: 23/265 at CB

Current Contract

(Extension, signed 2025)
(📝: indicates contract trigger occuring during that year)
YearAgeBase SalaryProrated Signing BonusPer Game Roster BonusGuaranteed SalaryCap
Number
Cap %
Dead Money & Cap Savings
202526$1,656,000$3,423,079$500,000$1,656,000$5,432,0201.9%
202627$9,000,000$2,500,000$500,000$9,000,000$12,000,0004.1%
2027 📝
March 17: $8.5 million becomes guaranteed
28$9,500,000$2,500,000$1,000,000$0$13,000,0004.2%
202829$9,500,000$2,500,000$1,000,000$0$13,000,000--
Total$29,656,000$10,923,079$3,000,000$10,656,000$43,432,020

Contract Notes

Jalen Pitre signed a three year, $39 million contract extension with the Texans on April 15, 2024. $29.156 million is guaranteed of which $20.656 million is fully guaranteed at signing. The new money guarantee is $25.5 million. Pitre received a $10 million signing bonus and his 2025 and 2026 salaries are fully guaranteed. He can earn an $8.5 million full guarantee on his 2027 salary.  There are annual per game bonuses worth up to $500,000 in 2025 and 2026 and up to $1 million in 2027 and 2028. The extension increased Pitre's 2025 salary cap number by $1 million.

Cash Flows

- fully earned money
- unearned or partially earned money
$13M
$26M
$39M
2025202620272028
Cash Due$8,500,000$9,500,000$10,500,000$10,500,000
Running Cash$8,500,000$18,000,000$28,500,000$39,000,000
Career Earnings: $17,028,376
Career APY: $5,676,125
Potential Earnings: $49,684,376
Total Guarantees: $27,684,376
Largest Cash Payment: $12,156,000 (2025)
Largest Cap Number: $13,000,000 (2027)

Contract History

TeamContract TypeStatusYear SignedYrsTotalAPYGuaranteesAmount Earned% EarnedEffective APY
TexansDraftedExtended20224$8,954,436$2,238,609$7,028,376$7,028,37678.5%$2,342,792
TexansExtensionActive20253$39,000,000$13,000,000$20,656,000$10,000,00025.6%$0
Earnings By Team
TeamYrsSalaryAPYPaid on Cap% Paid on CapPaid as Dead Money% Paid as Dead Money
Texans3$17,028,376$5,676,125$6,105,2970.0%$00.0%

Season History

YearTeamBase SalaryProrated BonusPer Game Roster BonusGuaranteed SalaryCap
Number
Cap %Cash Paid
2022Texans$705,000$923,079$0$705,000$1,628,0790.8%$4,397,316
2023Texans$1,112,020$923,079$0$1,112,020$2,035,0990.9%$1,112,020
2024Texans$1,519,040$923,079$0$1,519,040$2,442,1190.9%$1,519,040
2025Texans$1,656,000$3,423,079$500,000$1,656,000$5,432,0201.9%$12,156,000
2026Texans$9,000,000$2,500,000$500,000$9,000,000$12,000,0004.1%$9,500,000
2027Texans$9,500,000$2,500,000$1,000,000$0$13,000,0004.2%$10,500,000
2028Texans$9,500,000$2,500,000$1,000,000$0$13,000,000--$10,500,000
Total$32,992,060$13,692,316$3,000,000$13,992,060$49,537,317$49,684,376

Statistics

YearGames PlayedGames InactiveSnapsTacklesNegative PlaysInterceptionsFumblesTD
InjuredHealthyDefenseSpecialSoloAssistSacksYardsTFLQB HitsPass Def.INTYardsForcedRec.Yards
2022170092.9%1.9%994818518500100
2023151176.9%11.7%582600625001100
2024120160.3%1.7%442100628101000

Valuation Diamond

The diamond is a scatterplot graph that visualizes the relation of the player's APY (in green) and performance (in blue, as measured by OTC's Valuations) to the rest of the league at his position. To understand how to read the diamond, read this explainer.

OTC ValuationAPY
Regular$1,440,000$13,000,000
Injury Adjusted$1,440,000$13,000,000
test
OTC Valuation $3M $5.9M $8.9M $11.8M $14.8M APY $5M $10M $15M $20M $25M $4,410,000 $5,500,000

Weekly Valuation Trends

The chart below illustrates the trend of the player's weekly OTC Valuations (in blue) from the most recent season, using APY (in green) and, if applicable, cash that is due to the player in the next season (in red) as benchmarks. Weeks not plotted indicate that the player was inactive or on a bye.

To see interactive and more in-depth use of OTC Valuation data, subscribe to OTC Premium.